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Interest in Brucella species as a biological weapon stems 
from the fact that airborne transmission of the agent is 
possible. It is highly contagious and enters through mucous 
membranes such as the conjunctiva, oropharynx, 
respiratory tract and skin abrasions. It has been estimated 
that 10-100 organisms only are sufficient to constitute an 
infectious aerosol dose for humans. Signs and symptoms are 
similar in patients whatever the route of transmission and 
are mostly non-specific. Symptoms of patients infected by 
aerosol are indistinguishable from those of patients infected 
by other routes. Regimens containing doxycycline plus 
streptomycin or doxycycline plus rifampin are effective for 
most forms of brucellosis. Isolation of patients is not 
necessary. Trimethoprim-sulfamethoxazole and 
fluoroquinolones also have good results against Brucella, 
but are associated with high relapse rates when used as 
monotherapy. The combination of ofloxacin plus rifampicin 
is associated with good results. Even if there is little 
evidence to support its utility for post-exposure 
prophylaxis, doxycycline plus rifampicin is recommended 
for 3 to 6 weeks. 
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Introduction 
Brucellosis (also named Mediterranean fever, Gibraltar fever, 
Malta fever, Cyprus fever, undulant fever and typhomalarial 
fever) is a zoonotic infection caused by bacteria from the 
Brucella sp. Currently, of the six main biovars of Brucella, four 
are associated with moderate-to-significant human 
pathogenicity [1]. These biovars are found in goats and cattle 
(B. melitensis), swine (B. suis), cattle and bisons (B. abortus) 
and dogs (B. canis). B. melitensis occurs more frequently in 
humans than any of the other types and is the most virulent, 
pathogenic and invasive species, followed by B. suis,  B. 
abortus and B. canis. There is an epidemiological link with 
consumption of raw milk from cattle infected with B. abortus 
and human cases of brucellosis [1]. Abortions are common in 
animals infected with any Brucella species, but not in similarly 
infected pregnant women [1,2]. 
The infection occurs worldwide in both humans and animals, 
but is most common in the Mediterranean countries of Europe 
and Africa, the Middle East, India, Central Asia, Mexico, and 
Central and South America [2]. 
Transmission of brucellosis to humans is usually the result of 
ingestion, direct contact via cuts or abrasions of the skin, 
mucous membranes or inhalation [1,2]. Risk factors for 
infection include handling of infected animals (tissues and 
body fluids such as blood, urine, vaginal discharges, aborted 
animal foetuses and especially placentae), ingestion of 
contaminated animal products such as meat, raw or 
unpasteurised milk and milk products [1]. Persons at high risk 
are those working (farmers, veterinarians, abattoir workers) with 
infected agricultural animals such as cattle, pigs, sheep, camels 
and goats. Brucella  is one of the most common organisms 
acquired due to laboratory exposure usually by aerosolisation 
[3]. Airborne infection has also been reported in pens and 
stables of infected animals. Outbreaks of brucellosis are usually 
reported after inhalation of aerosols. Rare cases have occurred 
from accidental self-inoculation of the B. abortus vaccine strain 
19 and the B. melitensis animal vaccine strain Rev-1 [4,5]. 
Person-to-person transmission usually does not occur, with the 
exception of the very rare cases reported following blood 
exposure, primary exposure to infected tissues or after sexual 
contact. 
 
Brucellosis and bioterrorism 
Interest in Brucella species as a biological weapon stems from 
the fact that airborne transmission of the agent is possible (e.g. 
human airborne transmission during abortions of infected 
animals, aerosolisation in laboratories). It is highly contagious, 
as it can enter through mucous membranes such as the 
conjunctiva, oropharynx, respiratory tract and skin abrasions. It 
has been estimated that only 10-100 organisms are needed to 
constitute an infectious aerosol dose for humans [2]. Brucella is 
sensitive to exposure to heat and most disinfectants but can 
survive in the environment for up to two years under specific 
conditions, becoming a continuing threat to both humans and 
animals. In 1954, B. suis became the first agent weaponised by 
the United States (US). Several other countries have or are 
suspected to have weaponised this agent, including the United 
Kingdom (UK), although to our knowledge, this agent has never 
been used as a biological weapon [6]. Nevertheless, Brucella, 
particularly B. melitensis and B. suis, is considered one of the 
agents of lesser threat. The incubation period is rather long, 
many infections are asymptomatic and the mortality is low. 
However, the agent might be used more as an incapacitating 
agent, as the disease is associated with a high morbidity 
combining a protracted illness.  
 
Microbiological characteristics 
Brucella  is a small, Gram negative aerobic coccobacillus that 
grows extra- and intracellularly within macrophages. It lacks 
capsule, flagellae, endospore or native plasmid. The genus 
Brucella contains six species with multiple biotypes that vary in 
terms of biochemical reactions, host specificity and 
pathogenicity for humans [1]. The species affecting humans are 
mentioned above, while B. ovis and B. neotomae are not 
infectious for humans.  
The principal virulence factor of Brucella is the cell-wall 
lipopolysaccharide. Strains with smooth lipopolysaccharide are 
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 more virulent and more resistant to intracellular destruction by 
polymorphonuclear leukocytes. 
 
Clinical features 
Signs and symptoms are similar in patients whatever the route 
of transmission and are mostly non-specific (TABLE I). 
Symptoms of patients infected by aerosol are indistinguishable 
from those of patients infected by other routes [2]. Physical 
examination is usually without abnormalities A high degree of 
suspicion is imperative in order to establish the diagnosis.  The 
incubation period of brucellosis is highly variable, from one to 
60 days, up to several months, with an average of 1-2 months. 
The illness may be mild and self-limited or severe. Onset of the 
disease may be abrupt or insidious (50%). Brucellosis is a 
systemic infection that can involve any organ or organ system. 
It is generally characterised by fever, which may be continuous, 
intermittent or irregular [1]. Fever, which is the most common 
symptom (90%-95%), may be associated with other symptoms 
such as weakness, profuse sweating (40%-90%), chills, diffuse 
or localised arthralgias (20%-40%), malaise (80%-95%), 
weight loss and generalised pain (40%-70%) [2,7-9]. 
Neuropsychiatric complaints, which include headache, 
depression and irritability, are frequent. Gastrointestinal 
symptoms such as anorexia, nausea, vomiting, abdominal pain, 
diarrhoea or constipation are also frequent (up to 70% of 
cases). Rare cases of ileitis, colitis or peritonitis have been 
reported with B. melitensis [1]. The liver is involved in the 
great majority of cases as shown by a mild increase of liver 
function enzymes.  Non-caseating epithelioid granulomas 
indistinguishable from the ones seen in sarcoidosis can be 
found in liver biopsy.  Hepatic abscesses and acute 
cholecystitis have also been reported. Cough and chest pain are 
present in 15%-25% of infected patients with a normal chest 
radiograph [1]. Lung abscesses, nodules and pleural effusions 
have been reported. Lymphadenopathies are present in 10%-
20% of patients and 20%-70% experience splenomegaly and/or 
hepatomegaly (10%-30%). Cutaneous manifestations may 
include ulcerations, petechiae, purpura, and erythema nodosum. 
Osteoarticular complications of brucellosis are common (up to 
40%) and include sacroileitis, which represents the most 
frequently involved joint, peripheral joint arthritis, bursitis, 
osteomyelitis and particularly vertebral osteomyelitis or 
spondylitis (6%) [1,10,11]. Arthritis of peripheral joints usually 
involves large joints such as the hips, knees and ankles. 
Osteoarticular complications are usually due to B. melitensis. 
Other complications such as epididymo-orchitis, meningitis 
(manifested by lymphocytic pleocytosis, elevated protein and 
normal-low glucose in the CSF), encephalitis, seizures and 
neuropathies are less frequent (<2%). Severe behavioural 
changes of unknown aetiology occur in some patients. 
Endocarditis occurs in approximately 2% of patients [1]. Other 
cardiovascular complications include myocarditis, pericarditis 
and aneurysms of the aorta and cerebral vessels [1].  
In brucellosis, routine laboratory tests are commonly non-
specific: mild elevation of serum lactate dehydrogenase and 
alkaline phosphatase [2]. Haematological abnormalities may 
include anaemia, neutropenia and thrombocytopenia [12]. 
The case fatality rate is very low in untreated patients (less than 
2%). It is usually due to B. melitensis endocarditis or 
meningitis. Nearly all patients respond to antibiotic treatment, 
with fewer than 10% manifesting relapses. The systemic 
symptoms may last for weeks or months. Most of the patients 
recover within a year, even without antibiotic treatment. 
 
Diagnosis 
The diagnosis of brucellosis should be considered in a patient 
with a chronic fever of unknown origin. Case definitions of 
brucellosis are listed in Tables 2 and 3. 
It is definitively established by culture of the organism, which 
can be most frequently recovered from blood or bone marrow 
specimens. Positive culture may require 4 to 7 days to grow 
Brucella (up to 40 days). Blood cultures are positive in 10%-
90% of patients and are not helpful for the initial diagnosis of 
the disease. More rapid detection of the organisms may be 
performed on BACTEC blood cultures [13]. 
Standard serological diagnosis using the tube agglutination test 
confirms the diagnosis when a single titre >160 is found or a 
four-fold rise in the antibody titre is noted between the onset of 
illness and convalescent-phase serum, collected 14-21 days 
after. ELISA and western blot are also available, but these 
methods lack standardisation. PCR may demonstrate the 
presence of the organism in some cases [2]. 
 
Treatment 
A six-week regimen containing doxycycline plus streptomycin 
or doxycycline plus rifampicin  are effective for most forms of 
brucellosis [2,14,15] (TABLE IV). Isolation of patients is not 
necessary. Patients with endocarditis, spondylitis or 
meningoencephalitis may need to be treated for longer. 
Endocarditis requires doxycycline plus streptomycin plus 
rifampicin and may nevertheless require valve replacement. 
Trimethoprim-sulfamethoxazole and fluoroquinolones also have 
good results against Brucella, but are associated with high 
relapse rates when used as monotherapy. The combination of 
ofloxacin plus rifampicin is associated with good results [15]. 
Even if there is little evidence to support its utility for post-
exposure prophylaxis, doxycycline plus rifampicin is 
recommended for 3 to 6 weeks [14,15]. 
There is currently no authorised human Brucella vaccine in the 
European Union or the US. There are some limited clinical data 
on a live, attenuated vaccine-candidate strain from the former 
Soviet Union and China. Due to the frequency of adverse events 
and the short duration of immunity, it seems that it is no longer 
used [16]. Sub-unit vaccine candidates have also been studied 
but evidence of efficacy is inconclusive. The potential to 
develop human Brucella vaccine is limited by the small market 
potential, which will probably restrict development efforts to 
national defence agencies only [16]. 
 
In conclusion, brucellosis has been reported as a possibility after 
a bioterrorist act. The agent is stable and could be transmitted by 
the airborne route. But the disease is associated with low 
mortality and has a comparatively limited impact. 
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 TABLE  1           
Summary of clinical and biological description of brucellosis 
 
Clinical picture 
Incubation period: from 1 to 60 days 
Symptoms  
non-specific similar, regardless of  the route of transmission 
•  fever: continuous, intermittent or irregular 
•  weakness, profuse sweating, chills, diffuse or localised arthralgia, malaise, weight loss 
•  neuro-psychiatric complaints (headache, depression, irritability) frequent 
•  gastrointestinal symptoms (anorexia, nausea, vomiting, abdominal pain, diarrhoea or constipation 
•  cough and chest pain are rare 
Physical examination 
•  usually normal  
•  lymphadenopathy, splenomegaly and/or hepatomegaly (10%-30%) 
Complications 
•  osteoarticular (sacroileitis, peripheral joint arthritis, bursitis, osteomyelitis and spondylitis) 
•  epididymo-orchitis 
•  meningitis, encephalitis, seizures    
•  endocarditis, myocarditis, pericarditis and aneurysms (aorta and cerebral vessels) 
Diagnosis 
•  Demonstration of a specific antibody response (>160 or 4-fold rise between acute and convalescent phase) 
•  Demonstration by immunofluorescence of Brucella sp. in a clinical specimen 
•  Isolation of Brucella sp. from a clinical specimen 
Management 
•  Antibiotics (see Table 4) and supportive care 
•  Spondylitis and endocarditis complications need long treatment courses and possibly surgical treatment 
•  Post-exposure prophylaxis: doxycycline and rifampicin (see Table 4) 
•  No approved human vaccine available 
 
 
 
TABLE  2           
Case definitions of suspected or confirmed cases of brucellosis  
 
Possible case 
•  NA  
Probable case 
•  A case that is epidemiologically linked to a confirmed case or 
•  A case that has supportive serology (isolated high titre) 
 
Confirmed case 
•  A clinically compatible illness that is laboratory confirmed 
•  isolation of Brucella sp. 
•  >4-fold rise in Brucella agglutination titre between acute and convalescent phase 
 
NA: Not applicable 
Source: [17,18] 
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TABLE  3           
Case definitions of brucellosis due to deliberate release 
 
Suspected deliberate release 
o  Large-scale outbreak of brucellosis, especially in areas where Brucella is not endemic 
o  Clusters of cases in unusual settings, such as: 
•  where Brucella is not endemic  
•  without a travel history to endemic areas 
•  without relevant epidemiological history (food consumption, sexual contact, etc) 
•  without a history of occupational or laboratory exposure  
•  where the cases are linked in time and place, especially geographically related groups of illness following a 
wind direction pattern 
 
 
TABLE  4           
Recommendations for treatment and post exposure prophylaxis of brucellosis  
 
    Treatment of suspected or 
confirmed clinical cases (6 weeks) 
Post-exposure prophylaxis  
(3-6 weeks) 
Adults  
Pregnant women  
It is 
recommended, 
when possible, to 
stop 
breastfeeding. 
First line 
treatment 
- Doxycycline: 100 mg IV bid 
followed by 100 mg bid per os 
and 
- Rifampicin: 10-15 mg/kg/day in 1 
or 2 doses, followed by 600-900 
mg per os once daily 
or 
- Gentamicin: 3-5 mg/kg IV once 
daily or 1.5-2.5 mg/kg twice daily 
(max 2 weeks) 
or 
- Streptomycin: 1 g IM once or 
twice daily (max 2 weeks) 
- Doxycycline: 100 mg bid per os 
and 
- Rifampicin: 600-900 mg per os 
once daily 
  Second line 
treatment or first 
line treatment as 
an alternative for 
pregnant women 
- Trimethoprim (6-8 mg/kg/day) + 
sulfamethoxazole (40 mg/kg/day) 
IV in 1 or 2 divided doses followed 
by Trimethoprim (6-8 mg/kg/day) 
+ sulfamethoxazole (40 mg/kg/day) 
per os in 1 or 2 divided doses 
and 
- Rifampicin: 10-15 mg/kg/day in 1 
or 2 doses, followed by 600-900 
mg per os once daily 
- Not recommended 
Children  First line 
treatment 
In children > 8 
years 
- Doxycycline:  
     . > 45 kg: idem adult 
     . < 45 kg: 2.2 mg/kg IV twice 
daily followed by 2.2 mg/kg per os 
twice daily 
and 
- Rifampicin: 10-15 mg/kg/day in 1 
or 2 doses, followed by 10-15   
mg/kg per os in 1 or 2 doses daily 
or 
- Gentamicin: 1-2.5 mg/kg IV 3 
times daily (max 2 weeks) 
or 
- Streptomycin: 15 mg/kg IM once 
or twice daily (max 2 g/d and max 
2 weeks) 
- Doxycycline:  
. > 45 kg: idem adult 
 . < 45 kg: 2.2 mg/kg per os twice 
daily 
and 
- Rifampicin: 10-15  mg/kg per 
os in 1 or 2 doses daily 
 First  line 
treatment 
In children < 8 
years 
- Trimethoprim (6-8 mg/kg/day) + 
sulfamethoxazole (30-40 
mg/kg/day) IV in 2 divided doses 
followed by Trimethoprim (6-8 
mg/kg/day) + sulfamethoxazole 
(30-40 mg/kg/day) per os in 1 or 2 
divided doses 
and 
- Rifampicin: 10-15 mg/kg/day in 1 
or 2 doses, followed by 10-15   
mg/kg per os in 1 or 2 doses daily 
- Trimethoprim (6-8 mg/kg/day) 
+ sulfamethoxazole (30-40 
mg/kg/day) per os in 1 or 2 
divided doses 
and 
- Rifampicin: 10-15  mg/kg per 
os in 1 or 2 doses daily 
Source: [14]       
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